Rezdiffra delivered $364M in Q2 2026 net sales (up 71% YoY), with over 49,000 active patients and strong market expansion. The company advanced its MASH pipeline, secured new patents, and maintains robust cash reserves, positioning for continued growth and future profitability.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.